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Naturally occurring CD4+ regulatory T (nTreg) 
cells that represent 5–10% of peripheral CD4+ 
T cells constitutively express the IL-2R α chain 
(CD25) and the Foxp3 transcription factor, and 
play a central role in maintaining self-tolerance 
in several models of autoimmunity (1–3). These 
nTreg cells acquire their immunosuppressive 
properties during normal thymopoesis, and 
  abrogation of their development or function 
correlates with increased immunity to tumors, 
allergens, grafts, and pathogens and provokes 
the induction of multiorgan autoimmunity. 
Thus, CD4+ nTreg cells survive in the periph-
ery poised to prevent potential autoimmune 
responses and immunopathology (4–8).
Persistent infections may represent a com-
promise between pathogen and host. While 
the host attempts to maintain strong eff  ector 
immunity against reinfection and limit pathol-
ogy due to an uncontrolled infl  ammatory 
  response (9), pathogens strive to subvert host 
immunity to actively promote immunosup-
pression and pathogen persistence (10). Many 
studies show that persistent pathogens establish 
chronic infections by engaging nTreg cells, 
which function to suppress host immunity and 
control excessive eff  ector immune responses 
(11–15). We have previously shown that nTreg 
cells are essential for the development and 
maintenance of chronic cutaneous infection in 
Leishmania major–resistant C57BL/6 mice (7, 
12). In this model, disease is initiated by an 
acute phase hallmarked by pathogen replica-
tion and followed by the establishment of a 
chronic phase characterized by the stable main-
tenance of a low number of parasites at the site 
of primary challenge, the absence of overt 
  pathology, and resistance to reinfection. Regu-
latory T cells rapidly accumulate at sites of 
  infection, where they suppress anti-pathogen 
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Pathogen persistence after clinical cure is a hallmark of many chronic infections. Previously, 
we showed that naturally occurring CD4+CD25+ regulatory T (nTreg) cells rapidly accumu-
late within chronic dermal sites of Leishmania major infection where they suppress anti-
pathogen CD4+ T cell responses, favor parasite persistence and dermal pathology, and 
consequently control concomitant immunity. Here, we postulated that chemokines might 
direct nTreg cell homing in sites of infection and show that CD4+CD25+ nTreg cells, com-
pared with normal CD4+ T cells, preferentially express the CCR5 chemokine receptor, which 
enables them to migrate in response to CCR5 ligands in vitro. We show that in contrast 
to their wild-type (WT) counterparts, CCR5−/− CD4+CD25+ nTreg cells resulted in an 
increased magnitude of parasite-specifi  c, interferon 𝗄–producing CD4+ T cells within 
infection sites, dramatically reduced parasite numbers, and potent resistance to infection, 
a fi  nding consistent with the clinical outcome of infected CCR5−/− mice. Interestingly, this 
resistance was related to an ineffi  cient migration of CCR5−/− nTreg cells to infected dermal 
sites compared with WT nTreg cells. Thus, this study shows that CCR5 directs the homing of 
CD4+CD25+ nTreg cells to L. major–infected dermal sites where they promote the estab-
lishment of infection and long-term survival of the parasite in the immune host.
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CD4+ T cell responses, favor the persistence of a small num-
ber of parasites within cutaneous lesions, and consequently 
control concomitant immunity, as mice lacking nTreg cells 
achieve sterile cure and lose immunity to a secondary infec-
tion. In this model, regulation was antigen specifi  c and par-
tially dependent on nTreg cell–derived IL-10 production 
(16, 17). However, the molecular basis dictating the homing 
of nTreg cells to infected sites is not fully understood.
The diff  erential ability of CD4+CD25− and CD4+CD25+ 
T cell subsets to resolve disease may in fact refl  ect diff  erences 
in their homing to lymphoid organs and sites of infl  amma-
tion. Lymphocyte homing and traffi   cking in infl  amed lym-
phoid and nonlymphoid tissues may be facilitated by the 
expression of distinct sets of chemokine receptors, which
provide directional cues for the migration and recruitment of 
T cells into sites of infl  ammation (18). Currently, the chemo-
kine basis of nTreg cell traffi   cking to sites of infl  ammation is 
not clearly understood (19). In vitro studies have shown that 
a large fraction of CD4+CD25+ T cells from human periph-
eral blood selectively express CCR4 and CCR8 and show a 
strong chemotactic response to CCR4 ligands(20), consistent 
with a CCR4-dependent recruitment of regulatory T cells in 
human ovarian carcinoma (21). Another study showed that 
CD4+CD25+CD62L+ T cells in prediabetic nonobese dia-
betic mice express high levels of CCR7, thus potentially mi-
grating toward the lymphoid chemokines CCL19 and CCL21 
(22). Recently, Kleinewietfeld et al. (23) have shown that 
CCR6 is expressed on a distinct subset of mouse and human 
nTreg cells with an eff  ector–memory phenotype and func-
tion that is enriched in peripheral blood and rapidly accu-
mulates in the central nervous system after the induction 
of experimental allergic encephalomyelitis. Bystry et al. (24) 
has shown that murine CD4+CD25+ T cells express CCR5 
and display in vitro responsiveness to CCR5 chemokines, 
whereas another study has indicated that CCR5 may be 
modulating nTreg cell activity in graft-versus-host disease 
(25, 26). Thus, chemokine receptors may endow nTreg cells 
with a competitive advantage over eff  ector T cells to migrate 
more effi   ciently to infl  ammatory sites where they prevent 
immune responses.
In this study, we sought to determine whether CCR5 is 
selectively expressed on nTreg cells and further characterize 
its functional signifi  cance in the context of an L. major infec-
tion in vivo. First, we show that CD4+CD25+ nTreg cells, 
in contrast to conventional CD4+ T cells, preferentially ex-
press the CCR5 chemokine receptor, which enables them to 
migrate in response to the CCR5 ligands in vitro. We also 
demonstrate that CCR5 defi  ciency is associated with an in-
crease in anti–L. major eff  ector T cell expansion and IFN-γ 
production within infection sites. Furthermore, we show that 
CCR5−/− CD4+CD25+ nTreg cells migrated less effi   ciently 
to infected dermal sites compared with WT nTreg cells, thus 
allowing the development of a high number of parasite-spe-
cifi  c, CD4+ eff  ector T cells and potent resistance to infec-
tion. Collectively, this study shows that CCR5 directs the 
homing of CD4+CD25+ nTreg cells to L. major–infected 
dermal sites where they promote the establishment of infec-
tion and ensure the long-term survival of the parasite in the 
immune host.
RESULTS
CD4+CD25+ nTreg cells express CCR5
Previously, we have shown that a rapid infl  ux of CD4+CD25+ 
nTreg cells occurs in infected dermal sites during the silent 
phase of disease, which is characterized by peak parasite num-
bers in the site of L. major infection before the onset of adap-
tive immunity (7). The early and preferential recruitment of 
nTreg cells to infected sites might be critical to the ultimate 
establishment of a state of immunosuppression that dampens 
anti-parasite immunity and favors the parasite persistence (7, 
12). As CCR5 has been proposed to infl  uence nTreg activity 
in graft-versus-host disease and tumor immunity, we hypoth-
esized that CCR5 may drive the recruitment of nTreg cells 
to infectious sites.
To validate the CCR5 expression on nTreg cells, we per-
formed quantitative real-time PCR analysis on total RNA 
isolated from resting or TCR-stimulated CD4+CD25− or 
CD4+CD25+ T cells (Fig. 1 A). In freshly isolated, 
  unstimulated CD4+CD25+ T cells, CCR5 mRNA levels 
were approximately fi  vefold greater than their CD4+CD25− 
T cell counterparts. By 12 h after TCR stimulation, CCR5 
Figure 1.  CD4+CD25+ regulatory T cells preferentially express 
CCR5. (A) CD4+CD25− (−) or CD4+CD25+ (+) T cells were isolated from 
the LNs of C57BL/6 mice by FACS and stimulated with 10 μg/ml of plate-
bound anti-CD3 and 5 ng/ml IL-2. At various time points after stimula-
tion, total RNA was isolated and real-time PCR analysis of CCR5 expression 
relative to 18S rRNA expression was performed. Similar results were 
  obtained in three additional experiments performed. Results represent 
the mean ± SD. **, P < 0.001, difference from WT mice. (B) CCR5 expres-
sion on resting (left) and anti-CD3–activated (right) CD4+Foxp3+ T cells. 
Cells were stained for intranuclear Foxp3 and surface CD4 and CCR5, 
and analyzed by FACS. Similar results were obtained in three separate 
experiments performed.JEM VOL. 203, October 30, 2006  2453
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mRNA levels in CD4+CD25+ nTreg cells were  20-fold 
greater than their CD4+CD25− T cell counterparts. After 
48 h of TCR engagement, CCR5 expression levels on 
CD4+CD25+ T cells, albeit fi  vefold lower than the 12-h 
time point, were nonetheless signifi  cantly greater (fourfold 
increase) than their CD4+CD25− counterparts. This pref-
erential CCR5 gene expression on nTreg cells is also 
  confi  rmed by our fi  nding that 1% of resting and 15% of 
  activated CD4+CD25+ nTreg cells preferentially express 
cell surface CCR5 (Fig. 1 B). Thus, although the expression 
of CCR5 on nTreg cells is detectable in the absence of 
  activation, its expression is signifi   cantly increased upon 
  antigen stimulation, consistent with a recent study from 
Bystry et al. (24).
CCR5 is required for CD4+CD25+ nTreg cell 
chemoattraction, but not suppression, in vitro
To directly determine whether the CCR5 mRNA is 
  translated into the functional protein in nTreg cells, we ex-
plored the chemotactic response profi  le of highly purifi  ed 
CD4+CD25− and CD4+CD25+ T cells to CCR5 ligands 
MIP-1α, MIP-1β, or RANTES (100 ng/ml) in transwell 
chambers (Fig. 2). CD4+CD25+ T cells exhibited almost a 
2.5-fold increased migratory capacity in the absence of che-
mokine stimulation compared with CD4+CD25− T cells 
(not depicted). Our results show that both resting and acti-
vated CD4+CD25− T cells migrated very poorly to every 
chemokine (Fig. 2 A). In stark contrast, 26, 36, and 21% of 
resting, unstimulated CD4+CD25+ T cells migrated in re-
sponse to MIP-1α, MIP-1β, or RANTES, respectively (P < 
0.003). Similarly, 81, 61, and 67% of anti-CD3–activated 
CD4+CD25+ T cells showed preferential chemotactic activ-
ity to MIP-1α, MIP-1β, or RANTES, respectively (P < 
0.007). The addition of neutralizing antibodies to these che-
mokines completely abrogated the migration of nTreg cells 
in this assay (not depicted). Using total CD4+ T cells, we ob-
served that MIP-1α, MIP-1β, or RANTES strongly induced 
the migration of a substantial population of Foxp3+CD4+ T 
cells (Fig. 2 B). This confi  rms that nTreg cells, in contrast to 
CD4+CD25− T cells, preferentially express CCR5 and re-
spond to its ligands.
As nTreg cell suppression occurs via a contact-dependent 
and cytokine-independent manner in vitro, we postulated 
that these cells could use CCR5 to localize in physical prox-
imity to target cells and engage in suppression. To this end, 
we isolated nTreg cells from WT or CCR5−/− mice and ana-
lyzed their ability to suppress proliferation of WT (Fig. 2 C, 
left) and CCR5−/− (Fig. 2 C, right) responder T cells. In 
all cases, CD4+CD25+ nTreg cells were equally capable of 
  suppressing anti-CD3–induced proliferation regardless of 
nTreg cell/responder ratios. In vitro neutralization of each 
chemokine failed to abrogate the suppressive activity of 
CD4+CD25+ T cells (not depicted). Collectively, these results 
show that CCR5 is not required for nTreg cell suppressive 
function in vitro but does promote nTreg cell chemoattrac-
tion to CCR5 ligands.
CCR5−/− mice are resistant to L. major infection
We next sought to examine the relative contribution of 
CCR5 expression on CD4+CD25+ nTreg cells in a low-
dose intradermal (i.d.) model of L. major infection in C57BL/6 
mice. WT and CCR5−/− C57BL/6 mice were infected with 
103 L. major metacyclics in one ear, and the parasite burden 
and disease severity were monitored 6 wk after infection. 
In WT mice, infection resulted in a transient pathology that 
coincided with an increase in the parasite burden (Fig. 3 A, 
left and right). Interestingly, CCR5−/− mice were readily 
able to control L. major infection since the parasite burden in 
infectious sites was signifi  cantly reduced compared with WT 
(P  < 0.009) and correlated with a reduced pathology 
throughout the course of infection (Fig. 3 A, left and right). 
These fi  ndings show that CCR5 is essential for parasite per-
sistence and the establishment of L. major infection in geneti-
cally resistant mice, consistent with the observation made by 
Sato et al. (27, 28).
Figure 2.  CCR5 is required for CD4+CD25+ regulatory T cell che-
moattraction, but not suppressive activity, in vitro. (A) CD4+CD25− 
or CD4+CD25+ T cells were isolated as described in Materials and meth-
ods. Resting or anti-CD3 activated (10 μg/ml in the presence of irradi-
ated, T cell–depleted spleen cells for 72 h) T cells were subjected to 
transwell migration assays in the presence or absence of 100 ng/ml 
MIP-1α, MIP-1β, or RANTES. Histograms show percentage of CD4+CD25− or 
CD4+CD25+ T cells that migrated toward CCR5 chemokines without (top) 
and with (bottom) anti-CD3 stimulation. Values above each histogram 
indicate chemotactic index for each chemokine. Results represent the 
mean ± SD. **, P < 0.001, difference from WT mice. (B) Chemotaxis as-
says were performed as in A, and migrated T cells were stained intranu-
clearly for Foxp3. Histograms show percentage of CD4+ T cells that are 
Foxp3+ or Foxp3− that migrated toward CCR5 ligands. Results represent 
the mean ± SD. **, P < 0.001, difference from WT mice. (C) CCR5 is 
not required for suppressive activity of CD4+CD25+ T regulatory cells. 
5 × 104 WT (left) or CCR5−/− (right) CD4+ responder T cells were stimu-
lated with 0.5 μg/ml anti-CD3 and 2 × 105 irradiated, T cell–depleted 
spleen cells in the presence of titrated numbers of WT (□) or CCR5−/− 
(■) CD4+CD25+ nTreg cells. Similar results were obtained in three 
additional experiments performed.2454  ROLE OF CCR5 IN TREG HOMING IN VIVO | Yurchenko et al.
In our low-dose murine model of L. major infection, the 
long-term persistence of parasites in infected sites is exqui-
sitely determined by an equilibrium that is established 
  between IFN-γ–producing CD4+ eff   ector T cells and 
IL-10–producing CD4+CD25+ nTreg cells (7). In this 
model, parasite growth or elimination is rapidly triggered if 
the activities of IFN-γ or IL-10 are, respectively, impaired. 
To determine if the increased resistance in CCR5−/− mice 
occurred as a result of a functional imbalance in the IFN-γ/
IL-10 regulatory axis, WT and CCR5−/− mice were infected 
i.d. with L. major, and the degree of anti-pathogen Th1 im-
munity was determined at 3 and 12 wk after infection (Fig. 3 B). 
At 3 wk after infection, CCR5−/− mice displayed a 2.7-fold 
increase in i.d. CD4+ T cells compared with infected WT 
mice (6.3 × 106 vs. 2.3 × 106 CD4+CD3+). Surprisingly, 
this increased accumulation of T cells in CCR5−/− mice 
also correlated with a 3.6-fold increased number of IFN-γ–
producing T cells in infected dermal sites compared with 
WT mice (79 × 103 vs. 22 × 103 TCRβ+ cells) at 3 wk after 
infection. CCR5−/− mice were highly resistant to infection 
as they had a signifi  cant reduction in the number of para-
sites  in dermal sites and surprisingly developed little or 
no overt pathology in contrast to WT mice (Fig. 3 A). This 
increased ability to control the parasite load in infected 
CCR5−/− mice compared with WT mice at 12 wk was asso-
ciated with a twofold increased accumulation of T cells in 
i.d. sites, which paralleled the kinetics of accumulation of 
IFN-γ–producing T cells in the site (48 × 103 vs. 23 × 103 
TCRβ+ cells) before parasite killing (Fig. 3 B). Interestingly, 
CCR5−/− mice also had a 6.2-fold decrease in the frequency 
of IL-10–producing T cells in dermal sites compared with 
WT mice (8.7 vs. 1.4% of CD3+ T cells), consistent with 
the decreased susceptibility to L. major typically seen in WT 
mice devoid of nTreg cells (Fig. 3 C). Thus, CCR5 defi  -
ciency perturbs the equilibrium between eff  ector and nTreg 
cells within sites of infection, amplifi  es local immune re-
sponses in favor of anti-pathogen immunity, and promotes 
parasite clearance.
CCR5−/− CD4+CD25+ regulatory T cells fail 
to promote parasite persistence
To directly assess the relative contribution of CCR5 
expressed by nTreg cells in host immunity and parasite per-
sistence, freshly isolated WT or CCR5−/− CD4+CD25−
eff  ector T cells were transferred into RAG−/− recipients ei-
ther alone or in combination with CD4+CD25+ T cells from 
naive WT or CCR5−/− C57BL/6 mice, and the severity of 
disease was monitored at various time points after infection 
(Fig. 4). At 3.5 wk after infection, the approximate time of 
peak parasite load establishment in C57BL/6 mice, recipients 
of either WT or CCR5−/− CD4+CD25− T cells alone har-
bored very few parasites in the site and developed minimal 
or no dermal pathology (not depicted). At the same time 
point, RAG−/− recipient mice reconstituted with either 
CD4+CD25−/CCR5−/− CD4+CD25+ or CD4+CD25−/
WT CD4+CD25+ cell populations displayed a similar ability 
to control infection and developed a transient dermal pathol-
ogy, which in each case was greater than in recipients of 
  either WT or CCR5−/− CD4+CD25− alone (Fig. 4 A and 
not depicted). At 7 wk after infection,  recipients re-
constituted with CD4+CD25−/WT CD4+CD25+ T cells 
developed a lesion similar to that seen in chronically infected 
Figure 3.  CCR5−/− mice are resistant to L. major infection. 
(A) Parasite load and lesion sizes in L. major–infected WT or CCR5−/− 
mice. Mice were infected i.d. in each ear with 103 L. major promastigotes, 
and at various time points after infection parasite load (left) and lesion 
size (right) were determined. For each genotype, four to fi  ve mice were 
analyzed at every time point. Results represent the mean ± SD. **, P < 0.001, 
difference from WT mice. (B) Accumulation of dermal CD4+CD3+ (●) and 
TCRβ+ IFN-γ–producing cells (◇) at 3 and 12 wk after infection in WT 
and CCR5−/− mice. Purifi  ed dermal cells were incubated overnight with 
L. major–infected BMDCs before labeling for CD4, CD3, or TCRβ surface 
markers and intracytoplasmic staining for IFN-γ. Numbers represent the 
absolute number of CD4+CD3+or TCRβ+IFNγ+ cells per ear. Dermal cells 
from six or eight ears were pooled. This experiment is representative of 
two distinct experiments. Results represent the mean ± SD. *, P < 0.01 
and **, P < 0.01, difference from WT mice at 3 and 12 wk. (C) Accumulation 
of IL-10–producing dermal CD3+ cells 12 wk after infection in WT and 
CCR5−/− mice. Purifi  ed dermal cells were incubated overnight with 
L. major–infected BMDCs before labeling for CD3 surface marker and 
intracytoplasmic staining for IL-10. Numbers represent the percentage of 
CD3+ IL-10+ cells per ear. Results represent the mean ± SD. **, P < 0.001, 
difference from WT mice. Similar results were obtained in three separate 
experiments performed.JEM VOL. 203, October 30, 2006  2455
ARTICLE
WT mice with >1,000 parasites persisting in the site (Fig. 4 B). 
In contrast, in the presence of CCR5−/− CD4+CD25+ 
T cells, RAG−/− recipient mice healed faster and completely 
cleared the parasites from the site of infection to an extent 
similar to WT mice devoid of nTreg cells (Fig. 4). Thus, 
CCR5 expression on nTreg cells contributes directly to con-
trolling anti-parasite immunity within infected sites.
CCR5-dependent homing of CD4+CD25+ regulatory T cells 
in infected dermal sites
Our studies clearly show that CCR5 defi  ciency alters the abi-
lity of nTreg cells to control L. major immunity. To directly 
address whether CCR5 dictates their migration from periph-
eral lymphoid compartments to sites of persistent infection, 
we used a Ly5 congenic transfer system to independently 
monitor nTreg and eff  ector T cells from WT and CCR5−/− 
mice at various time points after L. major infection. We co-
transferred at a 1:10 ratio CD4+CD25+ nTreg cells from naive 
Ly5.1+ WT or Ly5.2+ CCR5−/− mice and CD4+CD25− 
T cells from naive Ly5.1+ or Ly5.2+ WT mice into RAG−/− 
recipients, and the numbers of each subset were analyzed 
  during the accumulation of peak parasite numbers in infected 
dermal sites. By 3 wk after infection, the frequency of WT 
Ly5.1+CD4+CD25+ nTreg cells represented 44% of total 
CD4+ T cells in the infected dermis (Fig. 5 A). In contrast, 
the frequency of CCR5−/− Ly5.2+CD4+CD25+ T cells 
  decreased to 6%, representing a 7.3-fold decrease compared 
with the WT condition (Fig. 5 A), suggesting that CCR5 may 
be directing the homing of nTreg cells in L. major–infected 
sites during the silent phase of disease.
To examine the evolution of nTreg cell recruitment into 
infl  amed sites, we monitored the number of nTreg cells at 
diff  erent time points in the spleen, draining LN, and infected 
dermal sites (Fig. 5 B). At 1.5 wk after infection, during the 
silent phase of disease characterized by parasite growth, WT 
Figure 4.  CCR5−/− CD4+CD25+ regulatory T cells fail to promote 
parasite persistence. RAG2−/− mice were infected in one ear with 103 
L. major promastigotes. At the time of infection, WT CD4+CD25− T cells 
(3 × 105/mouse) were adoptively transferred together with CD4+CD25+ 
T cells (3 × 104/mouse) obtained from either WT (●) or CCR5−/− mice (○). 
(A) Lesion sizes were measured at various time points after infection. 
Results are shown as the mean ± SD of the induration (four to six mice 
per time point). (B) Parasite numbers were assessed at 7 wk after infection. 
Numbers represent the mean parasite number per ear (four mice per group). 
Results represent the mean ± SD. **, P < 0.01, difference from WT mice. 
Similar results were obtained in three separate experiments performed.
Figure 5.  CCR5-dependent homing of CD4+CD25+ regulatory 
T cells to infected dermal sites. Naive CD4+CD25+ T cells from Ly5.1 
WT or Ly5.2 CCR5−/− C57BL/6 mice and CD4+CD25− T cells from Ly5.1 
WT or Ly5.2 WT C57BL/6 mice were purifi  ed and coinjected i.v. at a ratio 
of 1 CD4+CD25+ for 10 CD4+CD25− (3 × 104/3 × 105) into RAG2−/− 
mice 1 d before i.d. infection with L. major. (A) Percentage of WT (Ly5.1+) 
or CCR5−/− (Ly5.2+) CD4+ nTreg cells in the infected ear 3 wk after infec-
tion. Values represent the mean of four to six ears. The numbers represent 
the percentage of positive events in the quadrant. (B) Percentage of WT or 
CCR5−/− nTreg cells in the skin, LN, and spleen during the course of the 
infection. Single cell suspensions from each tissue of individual mice were 
extracted and stained with anti–TCRβ chain, anti-CD4, and anti-Ly5.2/
Ly5.1 antibodies. Percentage of Ly5.2+/Ly5.1+ cells (nTreg) was calculated 
on TCRβ+CD4+ gated events. (C) Absolute numbers of WT or CCR5−/− 
nTreg cells in the skin, LN, and spleen during the course of the infection. 
Cells were analyzed as in B. Results represent the mean ± SD. *, P < 0.001 
and **, P < 0.001, difference from WT mice. Similar results were obtained 
in three experiments performed. 2456  ROLE OF CCR5 IN TREG HOMING IN VIVO | Yurchenko et al.
nTreg cells (Ly5.1+) represented 30% of CD4+ T cells in 
dermal sites, although they were undetectable in draining LN 
or spleen. The frequency of WT nTreg cells steadily increased 
to  30–40% of CD4+ T cells in the dermis and draining LN 
at 3 wk and remained at these levels at 5.5 wk after infection, 
during the stage of lesion formation and immune clearance of 
parasites, with the exception of the spleen where the percent-
age of WT nTreg cells represented 50% of T cells. At 10 wk, 
around the onset of the chronic phase, the Ly5.1+ cells (WT 
nTreg) represented  15% of the CD4+TCRβ+ T cells in 
the dermis and  25% in the LN. In addition, WT nTreg cells 
continued to accumulate effi   ciently in the spleen during acute 
and chronic phases of disease (50 vs. 15% at 10 wk). These quan-
titative changes were greatly due to the expansion or recruit-
ment of Ly5.2+ CD4+ eff  ector T cells in the site and not to a 
decrease in the absolute number of Ly5.1+ CD4+ nTreg cells 
(not depicted). In stark contrast, CCR5−/− nTreg cells (Ly5.2+), 
while being undetectable in the LN and spleen, represented 
15–20% of CD4+TCRβ+ T cells in dermal sites at 1.5 wk, with 
the frequency drastically declining to  5–7% of total CD4+ T 
cells at 3 and 5.5 wk after infection. During the chronic phase 
(10 wk), CCR5−/− nTreg cells (Ly5.2+) represented <5% of 
the CD4+TCRβ+ T cells in the site of infection. Surprisingly, 
CCR5−/− nTreg cells accumulated more effi   ciently than WT 
cells in the draining LN of infected mice at 3 wk (40 vs. 30%, 
respectively) and 5.5 wk (70 vs. 30%, respectively) after infec-
tion. At 10 wk after infection, CCR5−/− nTreg cells migrated 
less effi   ciently than their WT counterparts in the spleen during 
acute and chronic phases of disease (10 vs. 50% at 5.5 wk, and 
1 vs. 15% at 10 wk, respectively). These frequency changes 
  correlated with a decrease in the absolute number of Ly5.2+ 
T cells in these sites, particularly during the chronic phase of 
  infection (10 wk; Fig. 5 C). Thus, WT nTreg cells home initially 
to the infected site where they maintain themselves until the 
chronic phase of the infection, whereas CCR5−/− nTreg cells 
have a reduced capacity to home to similar environments and 
appear to accumulate in the draining LN. In summary, these 
studies show that CCR5 is directly responsible for the recruit-
ment of nTreg cells to L. major–infected dermal sites where they 
promote infection and parasite persistence.
L. major infection induces CCR5 chemokines
Our results show that CCR5 expression on CD4+CD25+ 
nTreg cells is essential for their traffi   cking from peripheral 
lymphoid tissues into infected dermal sites. We next wished to 
demonstrate that CCR5 ligands, such as MIP-1α, MIP-1β, or 
RANTES, are produced within the dermis after L. major infec-
tion and are responsible for the chemoattraction of CD4+CD25+ 
T cells to these sites. To this end, we transferred WT CD4+CD25− 
T cells from naive mice to infected RAG−/− recipients either 
alone or in the presence of WT CD4+CD25+ nTreg cells at 
a 1:10 ratio. To assess chemokine production within infected 
sites, we isolated the infected dermis at 14 and 28 d after infec-
tion and performed RT-PCR analysis for CCR5, MIP-1α, 
MIP-1β, or RANTES gene expression (Fig. 6). In contrast to 
un  infected RAG−/− recipients, which never expressed any 
chemokines, L. major infection of similar hosts resulted in a sig-
nifi  cant induction of MIP-1α, MIP-1β, or RANTES with 
gene expression levels being, respectively, 15-, 40-, and 45-fold 
higher than uninfected controls and peaking at 28 d after infec-
tion. Transfer of CD4+CD25− T cells resulted in a more rapid 
induction of MIP-1α, MIP-1β, or RANTES with gene ex-
pression levels being, respectively, 7-, 50-, and 45-fold higher 
than uninfected controls and peaking at 14 d after infection. 
  Interestingly, cotransfer of CD4+CD25−/CD4+CD25+ T cells 
resulted in a signifi  cantly greater induction of MIP-1α, MIP-
1β, or RANTES gene expression levels (respectively, 17-, 70-, 
and 75-fold higher than uninfected controls), peaking at 14 d 
after infection and correlating temporally with the increase in 
parasite burden and loss of disease control. Strikingly, RAG−/− 
recipient mice transferred with CD4+CD25+ nTreg cells alone 
also resulted in signifi  cant expression of each chemokine at ev-
ery time point and paralleled the expression of CCR5 (Fig. 6) 
and Foxp3 (not depicted) in these sites, suggesting that nTreg 
cells themselves may paradoxically be responsible for the induc-
tion of CCR5 chemokines. Overall, these studies demonstrate 
that expression of the CCR5 ligands are actively induced after 
L. major infection and are temporally correlated with the re-
cruitment of nTreg cells in infected skin where they promote 
the establishment of infection.
Figure 6.  L. major infection induces CCR5 chemokines. Infected 
RAG2−/− mice (n = 5 per group) received either no cells (□), WT 
CD4+CD25− T cells (3 × 105/mouse) alone (○), or CD4+CD25+ T cells 
(3 × 104/mouse) alone (●), or with a combination of CD4+CD25−/
CD4+CD25+ T cells (▲; 3 × 105/3 × 104/mouse). Uninfected RAG2−/− 
mice served as a negative control (◇). Lesion sizes were monitored 
weekly. RT-PCR analysis of CCR5, RANTES, MIP-1α, and MIP-1β gene 
expression relative to G3PDH expression was performed on total RNA 
isolated from the ears of various experimental groups obtained 14 or 27 d 
after infection. Results represent the mean ± SD. *, P < 0.01 and **, P < 
0.01, difference from recipient mice with no nTreg cells. Similar results 
were obtained in two separate experiments performed.JEM VOL. 203, October 30, 2006  2457
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DISCUSSION
CD4+ nTreg cells represent a critical peripheral switch in the 
control of immune responses to self-antigens as well as to a 
variety of pathogenic microorganisms (6, 29–37). Previously, 
we showed that the establishment of pathogen persistence 
within L. major–infected sites is dependent on a tight equilib-
rium between eff  ector and nTreg cells (7). The abrogation of 
nTreg cell function or IL-10 production promotes clearance 
of the parasite, whereas depletion of eff  ector cells or infl  am-
matory cytokines like IFN-γ promotes disease reactivation. 
Interestingly, nTreg cells preferentially accumulate in sites of 
L. major infection during phases of parasite expansion and 
  establishment of chronicity, in contrast to eff  ector T cells, 
which increase during the acute phase of disease character-
ized by increased anti-pathogen immunity. Thus, diff  erential 
chemokine receptor expression profi  les between diff  erent 
T cell subsets could explain potential traffi   cking diff  erences in 
vivo, as shown in other models (20, 23, 26, 38, 39).
In this study, we establish a novel relationship between 
CCR5-dependent chemotaxis and the development of 
  immunity in L. major infection, and show that this receptor 
regulates critical aspects of the disease. First, we show that 
CD4+CD25+ nTreg cells preferentially express CCR5 and 
respond very effi   ciently in vitro to its ligands MIP-1α, MIP-
1β, or RANTES. Consistent with the enhanced control of 
systemic Leishmania donovani infection and dermal L. major 
infection, we then show that CCR5−/− mice are resistant 
to L. major infection in contrast to their WT counterparts 
(27, 28). We also show that this increased resistance correlates 
with a signifi  cant reduction in the production of IL-10 by 
dermal CD4+ T cells and a predominant Th1 response in 
CCR5−/− mice. More importantly, CCR5−/− nTreg cells, 
in contrast to WT nTreg cells, migrated less effi   ciently to in-
fected dermal sites and failed to suppress parasite-specifi  c, 
IFN-γ–producing CD4+ T cells, thus resulting in potent re-
sistance to infection. Collectively, this study shows that 
CCR5 directs the recruitment of nTreg cells to L. major–
  infected dermal sites where they promote the establishment 
of chronic infection.
We establish CCR5 as a critical checkpoint infl  uencing 
the balance between regulatory and eff  ector T cells in infec-
tious sites. The rapid control of parasite load in CCR5−/− 
mice was associated with a signifi  cantly increased infi  ltration 
of CD4+ eff  ector T cells in infected dermal sites as well as an 
enhanced magnitude of IFN-γ–producing CD4+ T cells in 
response to L. major in CCR5−/− mice compared with con-
trol mice. IFN-γ could contribute indirectly to the resolu-
tion of L. major infection in CCR5−/− mice by sustaining the 
infl  ammatory response in these mice. Although CCR5 may 
contribute to the pathogenesis of infectious diseases by pro-
moting IFN-γ–producing Th1 responses, CCR5 defi  ciency 
actually augmented IFN-γ production by dermal CD4+ T 
cells, further supporting the notion that disease resistance is 
likely caused by a lack of nTreg cell–mediated regulation in 
infected sites. These results are consistent with the predomi-
nant Th1 response seen in a high-dose model reported by 
Sato et al. (28), but are contrasted by the apparent reduction 
of early antigen-specifi  c IFN-γ responses in the spleen of 
outbred CCR5−/− mice infected i.v. with a high dose of 
L. donovani. Our results show no impairment in the accumu-
lation of nTreg cells in the LN; however, we did see a reduc-
tion of parasite numbers in this site, without any apparent 
alterations in nTreg cell numbers in the LN (not depicted). 
This may suggest that the primary site is necessary for parasite 
maintenance in the LN, possibly by the creation of specifi  c 
priming conditions or favorable cytokine environment. The 
ability of CCR5−/− nTreg cells to migrate effi   ciently to the 
LN but not to the infected dermal site suggests that CCR5 
ligands produced in infected sites are needed to fully engage 
nTreg cells in these sites. Overall, CCR5 signals during pri-
mary challenge dampen anti-pathogen eff  ector mechanisms 
and control the intensity of the infl  ammatory response within 
L. major–infected sites.
Our data indicates that CCR5 defi  ciency results in a dras-
tic reduction in the production of IL-10 by dermal CD4+ T 
cells, an observation consistent with a reduction of nTreg cell 
function in infectious sites. A function for IL-10 in promot-
ing parasite persistence and susceptibility to L. major infection 
in both susceptible and resistant strains is well documented 
(40–42). We have previously shown that IL-10, which is 
produced by nTreg cells, contributes directly to parasite per-
sistence and concomitant immunity (7). The mechanism by 
which IL-10 allows parasite growth and survival is not fully 
defi  ned, but it is likely due to its potent deactivating role of 
infected APCs that would become unresponsive to activation 
by IFN-γ. These results support the notion that during the 
chronic phase of disease, IL-10–producing nTreg cells domi-
nate over eff  ector mechanisms producing IFN-γ. This im-
munosuppressive role for IL-10 is also applicable to other 
animal models of infection, in which the levels of IL-10 are 
highly predictive of the outcome of the clinical course infec-
tion (13). The development of nTreg cells in CCR5−/− mice 
is similar to WT mice, thus excluding the possibility that in-
herent diff  erences in nTreg cell development or maturation 
in WT and CCR5−/− mice underlie our fi  ndings. Our re-
sults do not exclude the possibility that CCR5 may have a 
direct impact on the expansion, survival, or function of nTreg 
cells in infl  ammatory settings. Although CCR5 defi  ciency 
decreases the cellular frequency of nTreg cells and conse-
quential IL-10 production in dermal sites, CCR5 signals may 
be required for the terminal diff  erentiation of IL-10–produc-
ing nTreg cells within infected sites, as recently suggested for 
conventional CD4+ T cell eff  ector functions (43).
We also show that the CCR5 chemokines MIP-1α, 
MIP-1β, or RANTES are actively induced after a low-dose 
L. major infection, consistent with those made in other stud-
ies using high-dose footpad infection models of other Leish-
mania strains (44–47). We also make the novel observation 
that this expression is temporally correlated with the recruit-
ment of nTreg cells in infected dermal sites. The cellular 
sources of these chemokines are unknown and may be pro-
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immune response, including activated eff  ector T cells, in-
fected macrophages, and dendritic cells (44). It is plausible 
that the initial infl  ammatory events after pathogen infection 
result in chemokine production by these cell types, which 
subsequently attracts nTreg cells to dampen local immune 
responses. Strikingly, the presence of nTreg cells alone or in 
the presence of eff  ector T cells appeared to signifi  cantly in-
crease the expression of each chemokine in infected sites, 
suggesting that nTreg cells themselves may paradoxically 
produce or induce the synthesis of the chemokines. Thus, 
CD4+ nTreg cells may represent a functionally diversifi  ed 
population consisting of diff  erent subsets, such that some are 
responsible for the initial chemokine release whereas others 
are endowed with chemokine responsiveness.
Persistent infections such as AIDS, tuberculosis, and leish-
maniasis may represent a compromise between pathogen and 
host, such that the former subverts host immune responses to 
promote pathogen replication, whereas the latter maintains 
strong eff  ector immunity against reinfection while limiting 
potential immunopathology (10). The cellular and molecular 
mechanisms underlying the establishment, maintenance, and 
disruption of the homeostatic balance between host and 
pathogen remain poorly understood. Many studies indicate 
that pathogens may establish chronic infections in immuno-
competent hosts by engaging various regulatory T cells to 
promote immunosuppression and pathogen persistence. Our 
fi  ndings show that CCR5 expression on nTreg cells is a criti-
cal requirement for the establishment of chronicity in an im-
mune host and shed light into the overall dynamics of T cell 
responses in infected sites. On the basis of these results, it can 
be envisaged that transient CCR5 blockade may lead to the 
development of novel immunotherapeutic strategies for vari-
ous infectious diseases.
MATERIALS AND METHODS
Mice. WT, CCR5−/−, Ly5.1 congenic C57BL/6, and C57BL/10 RAG2−/− 
mice were obtained from the National Cancer Institute and The Jackson 
Laboratory. All mice were bred and maintained in a specifi  c pathogen-free 
animal facility. All mice used were generally 6–8 wk of age. All procedures 
conformed to the norms of the McGill University Animal Care Committee.
L. major  infections and parasite quantitation. Infective, metacyclic 
L. major promastigotes (clone V1 MHOM/IL/80/Friedlin) were grown and 
isolated from 4–5-d-old stationary cultures by negative selection of infective 
forms using peanut agglutinin (Vector Laboratories) as described previously 
(48). Mice were infected in the ear dermis with 103 L. major metacyclic pro-
mastigotes in a volume of 10 μl, and parasitic loads in the ears were deter-
mined as described previously (12, 16). In brief, the ventral and dorsal sheets 
of the infected ears were separated and deposited dermal side down in 
DMEM containing 100 U/ml penicillin, 100 μg/ml streptomycin, and 
50 μg/ml of liberase CI enzyme blend (Boehringer). Ears were incubated for 
2 h at 37°C. The sheets were cut into small pieces using a Medimachine 
(Becton Dickinson). The tissue homogenates were fi  ltered using a 70-μm 
cell strainer (Falcon Products Inc.) and serially diluted (increment 2) in a 
96-well fl  at-bottom microtiter plate containing biphasic medium prepared 
using 50 μl NNN medium containing 20% of defi  brinated rabbit blood 
overlaid with 100 μl M199/S. The number of viable parasites in each ear 
was determined from the highest dilution at which promastigotes could be 
grown out after 7 d of incubation at 26°C. The number of parasites was 
also determined in the local draining LNs (retromaxilar). The LNs were 
  mechanically dissociated and the parasite load in LN cells was determined 
by limiting dilution as   described above.
Flow cytometry of dermal T cells. For the analysis of surface markers 
and intracytoplasmic staining for IFN-γ or IL-10, dermal single cell suspen-
sions were stimulated with L. major–infected or soluble leishmania antigen–
stimulated bone marrow–derived dendritic cells (BMDCs) for 12–18 h as 
described previously (16). During the last 4–6 h, cells were cultured with 
10 μg/ml brefeldin A, fi  xed in 4% paraformaldehyde, and incubated with an 
anti–Fcγ III/II receptor in staining buff  er as described previously (21). Cells 
were permeabilized and stained with a variety of antibodies: CD3 (145-
2C11, FITC), CD4 (RM4-5, PE), IFN-γ (XMG1.2, PE), IL-10 (JES5-
16E3, PE), TCRβ (H57, APC), or rat IgG2b (A95-1) and rat IgG2a 
(R35-95; all from BD Biosciences) isotype controls. Staining for the nuclear 
marker Foxp3 was performed as per the manufacturer’s protocol (eBiosci-
ence). Cell acquisition was performed using a FACSCalibur fl  ow cytometer 
(Becton Dickinson) and CELLQuest software.
Purifi   cation of CD4+ T cell subsets. CD4+CD25+ or CD4+CD25− 
T cells from appropriate mice were purifi  ed from a pool of LN cells on a 
FACSVantage cell sorter to a fi  nal purity of >98% as described previously 
(12). Irradiated (3,000 R), T-depleted spleen cells were used as APCs and 
were prepared by negative selection of Thy1.2+ on the AutoMACS mag-
netic separation system (Miltenyi Biotec). Responder T cells were purifi  ed 
by negative depletion of CD8+, DX5+, B220+, and I-Ab+ cells from LNs 
by AutoMACS.
In vitro proliferation assays. Proliferation assays were performed by cul-
turing 5 × 104 CD4+ T cells in 96-well fl  at-bottom microtiter plates in 
complete RPMI 1640 (Invitrogen) supplemented with 10% heat-inactivated 
FCS, with 1–2 × 105 irradiated T-depleted spleen cells and 0.5 μg/ml of 
soluble anti-CD3 for 72 h at 37°C in 7% CO2. Cell cultures were pulsed 
with 1 μCi  3H-TdR for the last 6–12 h. All data represent the average 
counts per minute of triplicate determinations. All proliferation experiments 
were repeated at least three times.
Adoptive cell transfers. CD4+CD25+ or CD4+CD25− T cells (2–3 × 
105/mouse) were transferred i.v. to RAG−/− mice at various time points 
  after i.d. L. major infection as described previously (7).
RT-PCR. Evaluation of CCR5 gene expression was performed as follows. 
Total RNA was prepared from ear tissues or T cell cultures with the Trizol 
RNA extraction reagent, and cDNA was made using Superscript II with 
random hexamer primers (Invitrogen). Real-time PCR was performed us-
ing primers and a 6-carboxyfl  uorescein (FAM)-labeled probe for CCR5: 
forward primer, 5′-T  G  A  C  G  T  C  A  C  T  G  G  A  G  T  T  G  T  A  C  G  G  -3′; reverse primer, 
5′-G  G  T  T  C  A  T  G  T  C  A  T  G  G  A T  G  G  T  G  C  -3′; probe, 5′-FAM-T  T  C  A  G  C  G  C  T-
C  A  C  T  G  C  T  C  T  T  G  T  G  A  C  A  G  -TAMRA-3′ (Applied Biosystems). All PCR 
reactions were performed in triplicate using a TaqMan universal PCR mas-
ter mix amplifi  ed with an ABI Prism 7700 Sequence Detection System 
for 40 cycles and quantifi  ed using standard curves for CCR5 and TaqMan 
Ribosomal RNA Control Reagents (Applied Biosystems). RT-PCR prim-
ers for MIP-1α, MIP-1β, RANTES, CCR5, Foxp3, and G3PDH were ob-
tained from BD Biosciences. PCR products were electrophoresed, and 
semiquantitative analysis of gene expression was achieved by normalizing the 
test amplicon densitometric value with the intensity of the G3PDH ampli-
con for each sample by the Quantity One 4,4,1 software (Bio-Rad Laboratories) 
as described previously (29).
Migration assays. Migration assays were done in 6.5-mm diameter, 
5.0-μm pore size polycarbonate membrane fi  lter transwell plates (Costar 
Corning). The lower well chamber contained 0.6 ml RPMI medium with 
respective chemokines (100 ng/ml). All chemokines were purchased from 
PeproTech. T cell suspensions (0.1 ml at 107 cells/ml) were added to the 
upper chamber. After incubation for 3 h at 37°C and 10% CO2, the cells JEM VOL. 203, October 30, 2006  2459
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  migrated into the lower chamber, were stained with anti-CD4 (L3T4, FITC) 
and anti-CD25 (PC61, PE) or anti-Foxp3 (PE), and analyzed by FACS.
Statistical analysis. Results are expressed as mean ± SD. To determine 
whether diff  erences were statistically signifi  cant, the Student’s t test was 
  performed using a two-tailed distribution with unpaired samples. In some 
  instances, group comparisons were made by ANOVA or Kruskal-Wallis, 
followed by Dunnet’s test to determine diff  erences between genotypes.
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